Capricor Therapeutics
CAPR
115 hedge funds and large institutions have $104M invested in Capricor Therapeutics in 2025 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 26 increasing their positions, 36 reducing their positions, and 26 closing their positions.
31% more call options, than puts
Call options by funds: $33.9M | Put options by funds: $25.9M
31% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 26
7% more funds holding
Funds holding: 107 → 115 (+8)
1.54% more ownership
Funds ownership: 30.08% → 31.62% (+1.5%)
24% less capital invested
Capital invested by funds: $137M → $104M (-$32.4M)
28% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$3.55M |
| 2 |
DCM
DG Capital Management
New York
|
+$3.46M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.95M |
| 4 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$1.69M |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$4.9M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$3.13M |
| 3 |
JF
Jump Financial
Chicago,
Illinois
|
-$2.31M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$1.7M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$915K |
CAPR Hedge Fund Activity: Q3 2025 in Review
115 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q3 2025, worth a combined $104M — down 24% from $137M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new CAPR positions and 26 closed out — a net gain of 8 holders — while 26 added to existing stakes and 36 trimmed.
The largest buyer was J. Goldman & Co, opening a new position worth an estimated $3.55M. The largest seller was State Street, cutting an estimated $4.9M.
- 115 institutional investors held Capricor Therapeutics (CAPR) as of Q3 2025, up from 107 in Q2 2025.
- Funds reported $104M of Capricor Therapeutics stock for Q3 2025, down 24% quarter-over-quarter.
- 34 funds opened new Capricor Therapeutics positions in Q3 2025 and 26 closed out, a net change of +8 holders.
- The largest Capricor Therapeutics buyer in Q3 2025 was J. Goldman & Co, an estimated $3.55M added.
- The largest Capricor Therapeutics seller in Q3 2025 was State Street, an estimated $4.9M sold.
Based on aggregated 13F filings for Q3 2025.